证券代码：000788 证券简称：北大医药 公告编号：2024-060 近日，北大医药股份有限公司（以下简称"公司"）收到国家药品监督管理 局核准签发的《药品注册证书》。现将相关情况公告如下： 一、药品基本情况 1、药品通用名称：盐酸帕罗西汀肠溶缓释片 英文名/拉丁名：Paroxetine Hydrochloride Enteric-Coated Sustained -Release Tablets 剂型：片剂 规格：25mg（按C19H20FNO3计） 注册分类：化学药品4类 北大医药股份有限公司 关于获得《药品注册证书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 盐酸帕罗西汀肠溶缓释片的获批进一步完善了公司在精神类领域的产品结 构，有利于提升公司在精神类治疗领域产品市场的竞争力，对公司未来业绩的提 升有积极作用。 四、风险提示 公司将尽快启动盐酸帕罗西汀肠溶缓释片的生产和销售工作，由于药品的生 产经营情况可能受市场环境变化等不确定性因素的影响，具有一定的不确定性， 敬请广大投资者谨慎决策，注意投资风险。 药品批准文号：国药准字H20249181 ...

Financial Performance - Revenue for Q3 2024 was ¥526,202,037.02, a decrease of 7.95% compared to the same period last year[2] - Net profit attributable to shareholders was ¥43,539,592.87, an increase of 202.39% year-over-year[2] - Basic earnings per share for Q3 2024 was ¥0.0731, reflecting a growth of 202.07% compared to the previous year[2] - Total operating revenue for the third quarter was ¥1,534,330,245.12, a decrease of 7.3% compared to ¥1,655,471,575.84 in the same period last year[16] - The net profit for the third quarter of 2024 was CNY 130,313,731.08, a significant increase from CNY 46,109,690.65 in the same period last year, representing an increase of approximately 182.5%[17] - Operating profit for the third quarter reached CNY 163,931,888.07, compared to CNY 65,000,552.83 in the previous year, marking an increase of about 152.3%[17] - Earnings per share for the third quarter were CNY 0.2187, up from CNY 0.0774 in the same quarter last year, representing an increase of approximately 182.5%[17] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥2,327,826,491.93, down 4.53% from the end of the previous year[2] - Total liabilities decreased to ¥791,597,294.77 from ¥1,016,874,986.96, indicating improved financial health[15] - Cash and cash equivalents in current assets were reported at ¥1,966,287,622.62, down from ¥2,052,936,020.77, reflecting liquidity challenges[15] - Cash and cash equivalents at the end of the period totaled CNY 330,178,314.04, down from CNY 513,512,422.27 at the beginning of the period, reflecting a decrease of approximately 35.6%[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥63,852,931.12, a significant increase of 464.24% year-over-year[5] - Cash flow from operating activities generated a net amount of CNY 63,852,931.12, a turnaround from a negative cash flow of CNY -17,530,455.81 in the same quarter last year[18] - The company experienced a net cash outflow from financing activities of CNY -61,945,566.84, compared to CNY -199,030,153.78 in the previous year, indicating an improvement in cash flow management[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 49,939, with the largest shareholder holding 22.22% of the shares[6] - The top shareholder, Southwest Synthetic Pharmaceutical Group Co., Ltd., holds 132,455,475 shares, representing 100% of its holdings[7] - Beijing Medical Management Co., Ltd. holds 70,328,949 shares, also representing 100% of its holdings[7] - As of the end of the reporting period, the total shares held by the top 10 shareholders amount to 132,455,475 shares, with 60,107,360 shares involved in margin trading[7] - A total of 27,565,085 shares held by Beijing Medical Management Co., Ltd. have been pledged[9] Expenses and Cost Management - The company reported a decrease in sales expenses by 55.00% to ¥168,872,186.41 for the year-to-date[5] - Total operating costs decreased to ¥1,371,419,826.74, down 13.8% from ¥1,591,060,483.98 year-over-year[16] - Gross profit margin improved to approximately 10.6% from the previous year's margin, reflecting better cost management[16] - The company reported a decrease in financial expenses, with interest expenses at CNY 2,421,511.97, down from CNY 5,481,854.12 in the previous year, a reduction of about 55.8%[17] Research and Development - Research and development expenses increased to ¥19,360,593.13, up from ¥14,096,917.97, highlighting a commitment to innovation[15] - Research and development expenses amounted to CNY 13,294,511.08, compared to CNY 13,816,597.37 in the same quarter last year, indicating a decrease of approximately 3.8%[17] Corporate Actions - The company’s wholly-owned subsidiary, Shanghai Founder TuoKang Trading Co., Ltd., has completed its deregistration[8] - The company received approval from the National Medical Products Administration for the registration of its product, Levocetirizine Hydrochloride Oral Solution, confirming compliance with registration requirements[11] - The company announced a cash dividend distribution plan for the 2023 fiscal year, proposing a distribution of RMB 0.26 per 10 shares, totaling approximately RMB 15.5 million based on a total share capital of 595,987,425 shares[11] - The company plans to distribute a cash dividend of RMB 0.50 per 10 shares for the first half of 2024, amounting to a total of approximately RMB 29.8 million, pending shareholder approval[11] - The company held its annual general meeting on June 27, 2024, where it elected the 11th board of directors and supervisory board members, ensuring governance continuity[10] - The company signed a fixed asset lease agreement with Chongqing Southwest Synthetic Pharmaceutical Co., Ltd., for a three-year term starting January 1, 2024, indicating strategic asset management[10] Other Financial Metrics - The company’s weighted average return on equity was 3.05% for Q3 2024, an increase of 2.01% compared to the previous year[2] - The total equity attributable to shareholders increased by 8.08% to ¥1,536,926,837.92 compared to the end of the previous year[2] - Non-recurring gains and losses totaled ¥481,704.02 for Q3 2024, with government subsidies contributing ¥524,003.91[3] - Long-term equity investments increased to ¥3,257,509.74, indicating a focus on strategic investments[15] - Non-current assets totaled ¥361,538,869.31, down from ¥385,350,105.31, showing a reduction in asset base[15] - Accounts receivable decreased from RMB 1.25 billion to RMB 1.20 billion, a reduction of about 3.8%[13] - Inventory increased from RMB 184.18 million to RMB 208.54 million, representing a growth of approximately 13.2%[13] - The company has completed the payment of overdue taxes and penalties totaling RMB 19.45 million, covering the period from 2019 to May 31, 2023[10]

证券代码：000788 证券简称：北大医药 公告编号：2024-056 本议案已经董事会审计委员会审议通过。 表决结果：赞成票 9 票，反对票 0 票，回避票 0 票，弃权票 0 票。 北大医药股份有限公司 第十一届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北大医药股份有限公司（以下简称"公司"）第十一届董事会第四次会议于 2024 年 10 月 24 日上午在重庆市渝北区金开大道 56 号两江天地 1 单元 10 楼会 议室以现场结合通讯方式召开。会议通知于 2024 年 10 月 15 日以传真、电子邮 件或送达方式发给各位董事。本次会议应出席董事 9 人，实际出席董事 9 人，其 中董事齐子鑫先生、袁平东先生、任甄华先生、贾剑非女士、张勇先生、毛润先 生、王唯宁先生以通讯方式参加会议，其余董事出席现场会议。本次会议由董事 长齐子鑫先生主持，公司部分监事、高级管理人员列席了本次会议。会议的召开 符合《中华人民共和国公司法》、《公司章程》等有关规定。 二、会议审议情况 1、审议通过《2024 年第三季度报告》 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2024 年第三次临时股东大会 2、股东大会的召集人：公司董事会 公司第十一届董事会第四次会议审议并通过了《关于召开 2024 年第三次临 时股东大会的议案》。 3、本次股东大会的召开符合《公司法》、《证券法》、《深圳证券交易所 股票上市规则》及《公司章程》等法律、法规、制度的相关规定。 证券代码：000788 证券简称：北大医药 公告编号：2024-059 关于召开2024年第三次临时股东大会的通知 北大医药股份有限公司 （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向全体股东提供网络形式的投票平台，股东可 以在网络投票时间内通过上述系统行使表决权。 （3）公司股东只能选择现场投票表决和网络投票中的一种表决方式。如同 一表决权出现重复投票表决的，以第一次投票表决结果为准。 6、本次股东大会的股权登记日：2024 年 11 月 5 日（星期二） 4、召开时间 现场会议召开时间：2024 年 11 月 ...

证券代码：000788 证券简称：北大医药 公告编号：2024-057 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、审议通过《2024 年第三季度报告》 公司董事会对 2024 年第三季度公司的实际经营情况进行了总结，并编制了 公 司 2024 年 第 三 季 度 报 告 。 相 关 内 容 参 见 公 司 同 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《2024 年第三季度报告》。 表决结果：赞成票 5 票，反对票 0 票，回避票 0 票，弃权票 0 票。 三、备查文件： 《第十一届监事会第四次会议决议》 特此公告。 一、会议召开情况 北大医药股份有限公司（以下简称"公司"）第十一届监事会第四次会议于 2024 年 10 月 24 日上午在重庆市渝北区金开大道 56 号两江天地 1 单元 10 楼会 议室以现场结合通讯方式召开。会议通知于 2024 年 10 月 15 日以传真、电子邮 件或送达方式发给各位监事。本次会议应出席监事 5 人，实际出席监事 5 人，其 中监事张必成先生、郑晓东先生以通讯方式参会 ...

证券代码：000788 证券简称：北大医药 公告编号：2024-055 北大医药股份有限公司 关于持股 5%以上股东股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于近日收到持股5%以上股东北大 医疗管理有限责任公司（以下简称"北大医疗"）的告知函，获悉北大医疗持有的 公司7,050,301股股份已办理质押。现将相关情况公告如下： 一、股东股份质押基本情况 1、本次股份质押基本情况 3、股东股份累计被质押情况 截至本公告披露日，北大医疗及其一致行动人所持公司股份累计被质押情况如 | | | | | | | | 已质押 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 股份 | | 情况 | | | | | | | | | | 情况 | | | | | | | | | | | | 占 | | | | | | | | 本次质押前质 | 本次质押后质 | | | | ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥1,008,128,208.10, a decrease of 6.99% compared to ¥1,083,854,155.88 in the same period last year[10]. - Net profit attributable to shareholders was ¥86,825,395.85, representing a significant increase of 173.46% from ¥31,750,299.56 in the previous year[10]. - The net profit after deducting non-recurring gains and losses reached ¥86,488,101.38, up 233.58% from ¥25,927,186.41 year-on-year[10]. - Basic earnings per share were ¥0.1457, up 173.36% from ¥0.0533 in the previous year[10]. - The company reported a net profit margin of approximately 10.99% for the first half of 2024, compared to 10.00% in the same period of 2023[110]. - The total comprehensive income for the first half of 2024 was CNY 86,792,633.13, compared to CNY 31,725,424.02 in the first half of 2023, reflecting an increase of 173.5%[112]. - The company's total profit for the first half of 2024 was CNY 109,694,316.46, up from CNY 45,412,018.17 in the first half of 2023, marking an increase of 142.3%[112]. Cash Flow and Assets - The net cash flow from operating activities improved to ¥51,569,414.20, a turnaround from a negative cash flow of ¥106,655,560.85 in the same period last year, marking an increase of 148.35%[10]. - Cash and cash equivalents at the end of the reporting period amounted to ¥426,798,453.64, representing 17.70% of total assets, a decrease of 1.05% from the previous year[38]. - Accounts receivable totaled ¥1,163,340,010.57, accounting for 48.26% of total assets, down by 2.88% year-over-year[38]. - Inventory increased to ¥221,630,056.51, representing 9.19% of total assets, an increase of 1.64% from the previous year[38]. - The company's total assets at the end of the reporting period were ¥2,410,723,081.95, a decrease of 1.13% from ¥2,438,286,126.08 at the end of the previous year[10]. Research and Development - In the first half of 2024, the company focused on enhancing its research and development capabilities, with a dedicated R&D organization and approximately 10,000 square meters of pilot and trial production facilities[20]. - The company increased its R&D investment by 18.70% to ¥9,226,381.24 from ¥7,772,598.65, reflecting a commitment to innovation[33]. - The company emphasizes a research and development model that includes both independent and collaborative efforts, with a focus on high-potential and high-value products[22]. - The company is committed to increasing its investment in research and development to enhance product quality and manufacturing capabilities[16]. Market and Industry Context - The pharmaceutical manufacturing industry in China is characterized by intense competition, with a large market size but low market concentration, leading to high production costs[16]. - The company primarily engages in the research, development, production, and sales of chemical drug formulations, pharmaceutical distribution, and medical services[15]. - The pharmaceutical manufacturing industry is considered a weak cyclical industry, demonstrating strong resilience against economic fluctuations[17]. - In 2024, the government introduced multiple policies aimed at optimizing drug pricing and procurement processes, impacting the pharmaceutical industry[18]. - The company is adapting to the evolving regulatory landscape, including the emphasis on drug price governance and the expansion of centralized procurement[19]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of ¥0.50 per 10 shares, totaling approximately ¥29,799,371.25 based on the total share capital of 595,987,425 shares[1]. - The company reported a cash dividend of 29,799,371.25 yuan, which represents 100% of the total distributable profit of 142,956,929.10 yuan[52]. - The company has established a cash dividend policy that aligns with its growth stage and significant capital expenditure plans, ensuring a minimum cash dividend ratio of 20%[52]. Risks and Challenges - The company faces risks from industry policy changes, including drug approval and pricing pressures, and plans to enhance product quality and accelerate new product development[43]. - Rising raw material costs and price reductions in pharmaceuticals pose risks, prompting the company to focus on new product launches and market promotion[44]. - The company is actively monitoring opportunities for product introduction and mergers and acquisitions to expand its market presence[44]. Corporate Governance and Compliance - The company guarantees the independence of its personnel, assets, finance, organization, and business from its controlling entity, North Medical Management[58]. - The company has established an independent financial department and accounting system, ensuring financial independence[58]. - The company has committed to avoiding competition with Beida Medical and its controlled entities post-transaction, ensuring that no direct or indirect competition arises[59]. - The commitments made by Fangzheng Group and Beida Medical have been fulfilled, with no violations reported during their tenure as controlling shareholders[60]. Legal and Contractual Obligations - The company is involved in a lawsuit where it is required to pay a quality assurance deposit of 45 million RMB, with the arbitration case concluded[66]. - The company has ongoing litigation with a claim amount of 2,649.29 million RMB, which is currently in the execution phase[66]. - The company has a long-term service contract with Beijing University International Hospital for the supply and logistics of medical equipment and consumables, with an estimated annual contract value of 30 million RMB[77]. Accounting and Financial Reporting - The company adheres to the accounting standards for enterprises, ensuring that the financial statements reflect a true and complete picture of its financial status[134]. - The financial statements are prepared based on the going concern principle, indicating no significant doubts about the company's ability to continue operations[132]. - The company recognizes revenue from the sale of pharmaceutical products at the point when products are delivered to the agreed location and accepted by the customer, with revenue confirmed upon receipt of payment or entitlement to receive payment[178].

北大医药股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | 重庆方港医药有 限公司 | 子公司 | 其他应收款 | 2,374.81 | 32.64 | | | 2,407.45 | 提供资金 | 非经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 总计 | - | - | - | 145,129.83 | 54,610.18 | 1,070.05 | 58,297.83 | 142,512.22 | | | [注] 公司子公司北医医药与国际医院开展设备融资租赁业务，租赁总金额含税 514 万元，截止 2024 年 6 月 30 日，对国际医院长期应收款余额 419.85 万元，2024 年 1-6 月确认租赁收入 含税金额为 19.66 万元。 法定代表人：袁平东 主管会计工作的负责人：赵全波 会计机构负责人：王勇 | 非经营性资金 占用 | 资金占用方 名称 | | 占用方与上 市公司的 关联关系 | 上市公司 核算的 会计科目 | 2024 年期 初占用资 金 | ...

证券代码：000788 证券简称：北大医药 公告编号：2024-051 北大医药股份有限公司 关于2024年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日召开第十 一届董事会第三次会议和第十一届监事会第三次会议，分别审议通过了《2024 年半年度利润分配预案》，该议案尚需提交公司股东大会审议。现将相关情况公 告如下： 一、2024 年半年度利润分配预案基本情况 根据公司 2024 年半年度财务报告（未经审计），公司 2024 年半年度合并报 表归属于公司股东的净利润为 86,825,395.85 元。其中，母公司实现净利润 56,294,865.11 元。截至 2024 年 6 月 30 日，公司合并报表累计未分配利润为 636,194,060.98 元，母公司报表累计未分配利润为 142,956,929.10 元。以合并 报表、母公司报表中可供分配利润孰低为基数，公司可供股东分配的利润为 142,956,929.10 元。 公司2024年半年度利润分配预案为 ...

证券代码：000788 证券简称：北大医药 公告编号：2024-050 北大医药股份有限公司 第十一届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开情况 北大医药股份有限公司（以下简称"公司"）第十一届监事会第三次会议于 2024 年 8 月 29 日上午 10:30 以通讯方式召开。会议通知于 2024 年 8 月 19 日以 传真、电子邮件或送达方式发给各位监事。本次会议应出席监事 5 人，实际出席 监事 5 人。会议由监事会主席张必成先生主持，公司监事会秘书列席了本次会议。 会议的召开符合《公司法》、《公司章程》等有关规定。 二、会议审议情况 公司利润分配预案为：以现有总股本 595,987,425 股为基数，以可供股东分 配的利润向公司全体股东每 10 股派发现金红利 0.50 元（含税），以此计算合计 拟派发现金红利为 29,799,371.25 元。本次利润分配不送红股，不以资本公积金 转增股本。若在分配预案实施前公司总股本由于可转债、股份回购、股权激励、 再融资新增股份上市等原因发生变化的，将按照分配总额不 ...